uniQure N.V. (NASDAQ:QURE) Receives $64.17 Consensus Target Price from Analysts

Shares of uniQure N.V. (NASDAQ:QURE) have been assigned a consensus rating of “Moderate Buy” from the seventeen analysts that are presently covering the stock, MarketBeat reports. One analyst has rated the stock with a sell rating, four have issued a hold rating and twelve have issued a buy rating on the company. The average 1-year target price among analysts that have covered the stock in the last year is $64.1667.

A number of research analysts have weighed in on QURE shares. Mizuho boosted their target price on shares of uniQure from $35.00 to $68.00 and gave the stock an “outperform” rating in a research report on Thursday, June 25th. Royal Bank Of Canada lifted their price objective on uniQure from $35.00 to $65.00 and gave the stock an “outperform” rating in a research note on Thursday, June 18th. Weiss Ratings reissued a “sell (e+)” rating on shares of uniQure in a research report on Friday, June 26th. Wall Street Zen upgraded uniQure from a “sell” rating to a “hold” rating in a research note on Saturday, March 28th. Finally, Barclays upgraded uniQure from an “equal weight” rating to an “overweight” rating and increased their target price for the company from $25.00 to $65.00 in a research note on Thursday, June 18th.

Insider Activity at uniQure

In other news, insider Kylie O’keefe sold 15,936 shares of the stock in a transaction that occurred on Thursday, June 11th. The stock was sold at an average price of $27.06, for a total value of $431,228.16. Following the completion of the sale, the insider directly owned 108,864 shares of the company’s stock, valued at approximately $2,945,859.84. This represents a 12.77% decrease in their ownership of the stock. The transaction was disclosed in a legal filing with the Securities & Exchange Commission, which can be accessed through this hyperlink. Also, CEO Matthew C. Kapusta sold 164,429 shares of the company’s stock in a transaction on Wednesday, June 17th. The shares were sold at an average price of $44.32, for a total transaction of $7,287,493.28. Following the transaction, the chief executive officer owned 558,810 shares of the company’s stock, valued at approximately $24,766,459.20. The trade was a 22.74% decrease in their ownership of the stock. The SEC filing for this sale provides additional information. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 433,229 shares of company stock valued at $17,944,799. 4.65% of the stock is owned by corporate insiders.

Institutional Inflows and Outflows

Several institutional investors and hedge funds have recently made changes to their positions in the stock. CIBC Private Wealth Group LLC acquired a new position in shares of uniQure during the third quarter valued at about $50,000. Torren Management LLC acquired a new stake in uniQure during the fourth quarter worth about $28,000. FNY Investment Advisers LLC increased its stake in uniQure by 76.7% during the third quarter. FNY Investment Advisers LLC now owns 1,654 shares of the biotechnology company’s stock valued at $96,000 after acquiring an additional 718 shares during the period. IFP Advisors Inc bought a new position in uniQure during the fourth quarter valued at about $48,000. Finally, Smartleaf Asset Management LLC acquired a new position in uniQure in the 4th quarter valued at approximately $48,000. Institutional investors own 78.83% of the company’s stock.

uniQure Stock Performance

NASDAQ:QURE opened at $40.25 on Monday. The company’s 50 day moving average is $34.78 and its 200-day moving average is $25.11. The company has a quick ratio of 10.40, a current ratio of 10.40 and a debt-to-equity ratio of 0.33. uniQure has a 12 month low of $8.73 and a 12 month high of $71.50. The firm has a market cap of $2.54 billion, a price-to-earnings ratio of -11.57 and a beta of 0.90.

uniQure (NASDAQ:QURE) last posted its quarterly earnings data on Tuesday, May 5th. The biotechnology company reported ($0.85) earnings per share (EPS) for the quarter, topping the consensus estimate of ($0.88) by $0.03. uniQure had a negative net margin of 1,154.42% and a negative return on equity of 145.81%. The business had revenue of $3.56 million during the quarter, compared to the consensus estimate of $5.21 million. Equities analysts anticipate that uniQure will post -3.56 EPS for the current year.

uniQure Company Profile

uniQure N.V. is a biotechnology company focused on the development and commercialization of gene therapies for patients with severe medical needs. Using its proprietary adeno‐associated viral (AAV) vector platform, the company designs single‐dose treatments aimed at addressing the underlying genetic causes of disease rather than solely managing symptoms. Its most advanced program, Hemgenix® (etranacogene dezaparvovec), received regulatory approval in the United States and Europe for adult patients with hemophilia B, marking one of the first gene therapies for a bleeding disorder to reach the market.

Beyond hemophilia B, uniQure’s pipeline includes preclinical and clinical-stage candidates targeting rare and debilitating conditions such as aromatic l-amino acid decarboxylase (AADC) deficiency, Huntington’s disease, and Parkinson’s disease.